Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Eliquis
Apixaban is an oral anticoagulant, belonging to the class of direct factor Xa inhibitors. It works by selectively and reversibly blocking the active site of factor Xa, a key enzyme in the blood coagulation cascade. This inhibition prevents thrombin generation and subsequent clot formation, making it effective in preventing and treating various thromboembolic conditions.
For reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Spinal or epidural hematomas may occur in patients treated with apixaban who undergo spinal puncture or neuraxial anesthesia or receive other spinal injections. These hematomas may result in long-term or permanent paralysis. Risk factors may include the use of indwelling epidural catheters, concomitant use of NSAIDs or other drugs that affect hemostasis, and traumatic or repeated epidural or spinal punctures. Monitor patients frequently for signs and symptoms of neurological impairment.
Outcome:
Increased bleeding risk
Mechanism:
Inhibition of CYP3A4 and P-glycoprotein
Outcome:
Increased bleeding risk
Mechanism:
Additive antiplatelet effect
Outcome:
Minimal interaction
Mechanism:
Not well established
Most likely new formulation: Extended-release formulation (Year 2026, 70% confidence)
Based on usage trends and clinical trial data, there is a 90% likelihood that apixaban will maintain its current FDA approval status for the next 5 years.
Anticoagulant, Factor Xa Inhibitor
Oxazolidinone